JP6588922B2 - ヒト化百日咳抗体及びその使用 - Google Patents

ヒト化百日咳抗体及びその使用 Download PDF

Info

Publication number
JP6588922B2
JP6588922B2 JP2016560673A JP2016560673A JP6588922B2 JP 6588922 B2 JP6588922 B2 JP 6588922B2 JP 2016560673 A JP2016560673 A JP 2016560673A JP 2016560673 A JP2016560673 A JP 2016560673A JP 6588922 B2 JP6588922 B2 JP 6588922B2
Authority
JP
Japan
Prior art keywords
antibody
humanized
seq
variable region
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016560673A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017511140A5 (enExample
JP2017511140A (ja
Inventor
メイナード，ジェニファー
グエン，アナリー
パドラン，エドゥアルド
ワーグナー，エレン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of JP2017511140A publication Critical patent/JP2017511140A/ja
Publication of JP2017511140A5 publication Critical patent/JP2017511140A5/ja
Application granted granted Critical
Publication of JP6588922B2 publication Critical patent/JP6588922B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1225—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Bordetella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2016560673A 2014-03-31 2015-03-31 ヒト化百日咳抗体及びその使用 Expired - Fee Related JP6588922B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461973141P 2014-03-31 2014-03-31
US61/973,141 2014-03-31
US201462046403P 2014-09-05 2014-09-05
US62/046,403 2014-09-05
PCT/US2015/023715 WO2015153685A1 (en) 2014-03-31 2015-03-31 Humanized pertussis antibodies and uses thereof

Publications (3)

Publication Number Publication Date
JP2017511140A JP2017511140A (ja) 2017-04-20
JP2017511140A5 JP2017511140A5 (enExample) 2018-04-26
JP6588922B2 true JP6588922B2 (ja) 2019-10-09

Family

ID=54241237

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016560673A Expired - Fee Related JP6588922B2 (ja) 2014-03-31 2015-03-31 ヒト化百日咳抗体及びその使用

Country Status (8)

Country Link
US (3) US9512204B2 (enExample)
EP (1) EP3126385B1 (enExample)
JP (1) JP6588922B2 (enExample)
CN (1) CN106459183B (enExample)
AU (1) AU2015240834B2 (enExample)
CA (1) CA2941152C (enExample)
ES (1) ES2755957T3 (enExample)
WO (1) WO2015153685A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2752396A1 (en) * 2010-09-17 2012-03-17 Board Of Regents, The University Of Texas System Pertussis antibodies and uses thereof
EP3126385B1 (en) * 2014-03-31 2019-09-18 Board Of Regents, The University Of Texas System Humanized pertussis antibodies and uses thereof
MD20160130A2 (ro) * 2014-04-27 2017-04-30 Ccam Biotherapeutics Ltd. Anticorpi umanizaţi contra CEACAM1
US11427647B2 (en) 2014-04-27 2022-08-30 Famewave Ltd. Polynucleotides encoding humanized antibodies against CEACAM1
CN107663240B (zh) * 2016-07-29 2021-01-12 中国人民解放军第四军医大学 高度糖基化cea特异性结合的单链抗体及其在检测和治疗上的应用
US20210332112A1 (en) * 2016-08-15 2021-10-28 Board Of Regents, The University Of Texas System Stabilized pertussis antibodies with extended half-life
US10538579B2 (en) 2016-08-15 2020-01-21 Board Of Regents, The University Of Texas System Bispecific pertussis antibodies
AU2018351072B9 (en) 2017-10-20 2024-09-05 Fred Hutchinson Cancer Center Systems and methods to produce B cells genetically modified to express selected antibodies
EP3995510A4 (en) * 2019-07-01 2023-11-08 Suzhou Alphamab Co., Ltd PERTUSSIS TOXIN BINDING PROTEIN
WO2024237730A1 (ko) * 2023-05-18 2024-11-21 한국과학기술연구원 항-엔도글린 항체 및 이의 용도

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1223529B (it) 1987-12-18 1990-09-19 Sclavo Spa Epitopo immunodominante protettivo contenuto nella subunita' s1 della tossina della pertosse
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
US7417133B2 (en) * 2004-02-27 2008-08-26 Institut Pasteur Methods for obtaining thermostable enzymes, DNA polymerase I variants from Thermus aquaticus having new catalytic activities, methods for obtaining the same, and applications of the same
WO2009042165A2 (en) * 2007-09-25 2009-04-02 Thomas Jefferson University Mutant botulinum neurotoxin serotype a polypeptide and uses thereof
CA2752396A1 (en) 2010-09-17 2012-03-17 Board Of Regents, The University Of Texas System Pertussis antibodies and uses thereof
WO2014160098A2 (en) * 2013-03-13 2014-10-02 Excelimmune, Inc. Bordetella specific human recombinant antibodies and uses thereof
EP3126385B1 (en) * 2014-03-31 2019-09-18 Board Of Regents, The University Of Texas System Humanized pertussis antibodies and uses thereof

Also Published As

Publication number Publication date
ES2755957T3 (es) 2020-04-24
US20170066816A1 (en) 2017-03-09
CN106459183B (zh) 2020-05-19
EP3126385A4 (en) 2018-02-21
JP2017511140A (ja) 2017-04-20
US9512204B2 (en) 2016-12-06
US20150353628A1 (en) 2015-12-10
AU2015240834B2 (en) 2020-02-27
CA2941152C (en) 2023-09-19
CA2941152A1 (en) 2015-10-08
US10035846B2 (en) 2018-07-31
EP3126385B1 (en) 2019-09-18
AU2015240834A1 (en) 2016-09-15
US20180362621A1 (en) 2018-12-20
US10526400B2 (en) 2020-01-07
CN106459183A (zh) 2017-02-22
WO2015153685A1 (en) 2015-10-08
EP3126385A1 (en) 2017-02-08

Similar Documents

Publication Publication Date Title
JP6588922B2 (ja) ヒト化百日咳抗体及びその使用
JP7550251B2 (ja) 糖尿病黄斑浮腫の治療のための組成物および方法
US10179821B2 (en) Anti-factor D antibodies
US8617548B2 (en) Methods of preventing or treating anthrax using anti-anthrax antibodies
KR20160047567A (ko) 조작된 항-dll3 접합체 및 사용 방법
CN106102837A (zh) 经由细胞受体锚定使用具有天然架构的双特异性抗体改良的hiv‑1‑中和抗体效力和广度
US20230181730A1 (en) Methods of treating infections
WO2011028961A2 (en) Anti-botulism antibody coformulations
EP3360896A1 (en) Antibody to hepatitis b surface antigen and use thereof
CA3115708A1 (en) Formulations of anti-rsv antibodies and methods of use thereof
JP2018531980A (ja) 抗ｄ因子抗体製剤
US20210332112A1 (en) Stabilized pertussis antibodies with extended half-life
US10538579B2 (en) Bispecific pertussis antibodies
ES2985731T3 (es) Tratamiento de exacerbaciones agudas de la enfermedad pulmonar obstructiva crónica mediante antagonismo de IL-20R
WO2014160098A2 (en) Bordetella specific human recombinant antibodies and uses thereof
CN116606373A (zh) 新型冠状病毒中和抗体及其用途
TW202317184A (zh) 用於治療異位性皮膚炎和相關障礙之方法
WO2021233408A1 (zh) 抗α-溶血素的抗体及其稳定制剂
JP7315259B2 (ja) 百日咳毒素結合タンパク質
JP2016527200A (ja) Ｃｄ３７抗体とクロラムブシルの併用
WO2025056005A1 (zh) 抗tim-3抗体的药物组合物及用途
GB2496854A (en) Anti-VEEV antibodies and their use in prophylaxis or treatment
BR112016022318B1 (pt) USO DE UM ANTICORPO QUE SE LIGA A UMA CALICREÍNA PLASMÁTICA ATIVA (PKal) E NÃO SE LIGA À PRECALICREÍNA HUMANA NO TRATAMENTO DE DOENÇAS DA RETINA
NZ744721A (en) Treatment for rheumatoid arthritis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180316

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180316

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190129

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190422

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190624

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190729

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190820

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190913

R150 Certificate of patent or registration of utility model

Ref document number: 6588922

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees